The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based study

Dahlén, Torsten; Flygt, Hjalmar; Lübking, Anna; Olsson‐Strömberg, Ulla; Wennström, Lovisa; Dreimane, Arta; Själander, Anders; Leach, Susannah; Gisslén, Magnus; Li, H.; Höglund, Martin; Stenke, Leif; Nyberg, Fredrik

doi:10.1038/s41375-023-01893-1

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering their increased risk of thrombosis compared to the general population, CML patients with COVID-19 interestingly are not reported to develop additional risk thrombotic events as might be expected. This finding is supported by the Sweden study (32), the study with the longest follow-up for patients with CML and COVID-19, starting from March 2020 to April 2023, showed that there is no significant adverse outcome when compared imatinib to the newer TKI, also the study showed CML patients with no vaccination, had a slightly higher risk of hospitalization compared to their controls (32). The study also raised the finding that few events were reported among these patients.…”

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

Ali,

Al-Sadi,

Al-maharmeh

et al. 2024

Front. Med.

View full text Add to dashboard Cite

IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus causing the coronavirus disease of 2019. The disease has caused millions of deaths since the first pandemic at the end of 2019. Immunocompromised individuals are more likely to develop severe infections. Numerous mutations had developed in SARS-CoV-2, resulting in strains (Alfa Beta Delta Omicron) with varying degrees of virulence disease severity. In CML (chronic myeloid leukemia) patients, there is a lot of controversy regarding the effect of the treatment on the patient outcome. Some reports suggested potential better outcomes among patients with CML, likely due to the use of TKI; other reports showed no significant effects. Additionally, it is unknown how much protection immunization provides for cancer patients.MethodIn accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, we conducted a systematic review. Retrospective, prospective studies, reviews, case series, and case reports of chronic myeloid leukemia patients aged above 18 years who had SARS-CoV-2 infection were included. English literature was screened using PubMed, SCOPUS, and Google Scholar. Search terms include chronic myeloid leukemia, chronic myelogenous leukemia, and SARS-CoV-2 and Coronavirus disease 2019 (COVID-19). We searched the reference lists of the included studies for any new articles. The search included all articles published up to April 20, 2023. The review is registered in PROSPERO (registration number CRD42022326674).ResultsWe reviewed 33 articles of available published literature up to April 2023 and collected data from a total of 682 CML patients with COVID-19. Most patients were in the chronic phase, seven were in the accelerated phase, and eight were in the blast phase. Disease severity was classified according to WHO criteria. Mortality was seen in 45 patients, and there were no reports of thrombotic events. Two hundred seventy-seven patients were in the era before vaccination; among them, eight were in the intensive care unit (ICU), and mortality was 30 (11%). There were 405 patients after the era of vaccination; among them, death was reported in 15 (4%) patients and ICU in 13 patients.Limitations and conclusionThe major limitation of this review is the lack of details about the use or hold of TKIs during SARS-CoV-2 infection. Additionally, after the appearance of the different variants of the SARS-CoV-2 virus, few studies mentioned the variant of the virus, which makes it difficult to compare the outcome of the other variants of the SARS-CoV-2 virus in patients with CML. Despite the limitations of the study, CML patients with COVID-19 have no significant increase in mortality compared to other hematological malignancy. Hematological cancers are associated with an increased risk of thrombosis, which is expected to increase in patients with COVID-19. However, patient with CML has not been reported to have a significant increase in thrombosis risk. The available data indicates that COVID-19’s effect on patients with chronic myeloid leukemia (CML) still needs to be better understood due to the limited data.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php? RecordID:326674.

show abstract

Section: Discussionmentioning

confidence: 71%

“…Many studies have tried to find an effective treatment that can reduce the mortality of COVID-19. Currently, there are many medications that have been shown to prove survival benefit in patients with severe COVID-19 pneumonia ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

Ali,

Al-Sadi,

Al-maharmeh

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

El-Ashwah,

Salmanton-García,

Bilgin

et al. 2023

Leukemia & Lymphoma

View full text Add to dashboard Cite

Comprehensive assessment of COVID-19 case fatality rate and influential factors in Khuzestan Province, Iran: a two-year study

Bastani,

Makvandi,

Moradi

et al. 2024

J Health Popul Nutr

View full text Add to dashboard Cite

Background The emergence of a new pandemic SARS-CoV-2 (COVID-19) resulted in a high mortality rate across the world. This study sought to comprehensively analyze the Case Fatality Rate (CFR) associated with COVID-19 in the Khuzestan province of Iran”. The primary objective was to discern patterns and determinants influencing CFR, shedding light on the evolving impact of the pandemic on morbidity and mortality. Methods A retrospective examination was performed on a dataset encompassing confirmed COVID-19 cases and related fatalities in Khuzestan. Data, spanning from December 2020 to April 2022, underwent rigorous statistical analysis. Demographic variables, comorbidities, and temporal trends were scrutinized to identify key factors influencing CFR. Results Preliminary findings revealed dynamic shifts in CFR, capturing the nuanced nature of the pandemic over time. Demographic nuances, particularly age and gender, emerged as significant determinants impacting CFR, the reported CFR of COVID-19 in Khuzestan province was 1.79%. Conclusion This study contributes critical insights into the CFR landscape of COVID-19 in Khuzestan, providing a foundation for evidence-based decision-making in public health. The identified factors influencing mortality rates offer valuable information for tailoring interventions and optimizing resource allocation. Continuous monitoring and further investigations are recommended to adapt strategies to the evolving nature of the pandemic.

show abstract

The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based study

Cited by 4 publications

References 8 publications

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Comprehensive assessment of COVID-19 case fatality rate and influential factors in Khuzestan Province, Iran: a two-year study

Contact Info

Product

Resources

About